 SOUTH SAN FRANCISCO, Calif., Dec. 02, 2020 GLOBE NEWSWIRE -- Allogene Therapeutics, Inc. Nasdaq: ALLO, a clinical-stage biotechnology company pioneering the development of allogeneic CAR T AlloCAR TTM therapies for cancer, today announced that management will review initial results presented at the American Society of Hematology Annual Meeting from the ALLO-715 UNIVERSAL Phase 1 trial in relapsedrefractory multiple myeloma on December 5, 2020 via a live webinar at 11:00 AM Pacific Time2:00 PM Eastern Time. 